VOGUE: Non-Inferior Efficacy of Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide in Adults With HIV-1 Naive to Treatment
Clicks: 8
ID: 322774
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
8 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #50 of 207 articles by views in Open forum infectious diseases
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 207 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Antiretroviral therapy (ART) that achieves virologic suppression using fewer antiretroviral agents is an optimized approach to HIV treatment initiation. VOGUE is the first randomized, head-to-head study comparing the 2-drug regimen dolutegravir/lamivudine (DTG/3TC) with the 3-drug regimen bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) as initial ART, including among individuals with high viral loads (VLs) and/or low CD4+ cell counts. Methods This phase 3b, randomized (1:1), open-label, non-inferiority study compared DTG/3TC vs BIC/FTC/TAF as first-line ART in adults with HIV-1. Participants were enrolled without baseline VL or CD4+ cell count restrictions and initiated treatment before availability of resistance testing results. The primary endpoint was the proportion of participants with HIV-1 RNA <50 copies/mL at Week 48 (Snapshot; -10% non-inferiority margin). Results Among 509 randomized participants (DTG/3TC, n=254; BIC/FTC/TAF, n=255), 47% had baseline VL ≥100,000 copies/mL and 16% had CD4+ cell count <200 cells/mm3. At Week 48, DTG/3TC demonstrated non-inferior efficacy to BIC/FTC/TAF, with HIV-1 RNA <50 copies/mL achieved in 89% and 92% of participants, respectively (adjusted difference, -3% [95% CI, -8%, 2%]). Median time to virologic suppression was rapid (4.1 weeks) in both groups. Confirmed virologic withdrawals were similar between groups (n=7 each), with no treatment-emergent resistance identified. Safety outcomes were comparable. Conclusions Dolutegravir/Lamivudine demonstrated non-inferior efficacy to BIC/FTC/TAF as initial ART, with no treatment-emergent resistance through Week 48. These findings establish DTG/3TC as an effective and simplified initial ART regimen across a broad clinical spectrum.
| Reference Key |
openalex_W7171558457
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Jade Ghosn, Federico Pulido, Gustavo Lopardo, Anita Olczak, Diego Ripamonti, Charlotte Martin, Orlando Paredes Ceballos, Hartmut Stocker, J Mendez, Hiroyuki Gatanaga, Symeon Metallidis, Daniel Elbirt, Gary Whitlock, José Ignacio Mateo González, Perry Mohammed, Kehui Wang, Richard Grove, Ruolan Wang, Adelaide Jewell, Kenneth Sutton, Emilie R Elliot, Riya Moodley, Rebecca Borsi, Bryn Jones, Michelle Kisare, Piotr Budnik, Jean van Wyk |
| Journal | Open forum infectious diseases |
| Year | 2026 |
| DOI |
10.1093/ofid/ofag471
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.